Financials

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Financials in One Page

GNFC is a ~$923M-revenue Gujarat-based commodity chemicals and urea fertilizer producer whose earnings power swings violently with TDI, aniline, methanol and acetic-acid spreads. The cycle peaked in FY2022 (revenue $1,141M, 28% operating margin, $1.45 EPS) and has since rolled over to a trough (FY2025 revenue $923M, 7.8% operating margin, $0.48 EPS). The fortress sits in the balance sheet: total debt has shrunk from $615M in FY2015 to just $12M in FY2025, against $270M of investments — a net-cash position equal to roughly 30% of today's market cap. Operating cash conversion has averaged 110%+ of net income across the cycle, but capex is now ramping (CCPP, Ammonia expansion, Weak Nitric Acid-III, Ammonium Nitrate-II, and BPA/Polyols under consideration) and FY2024 free cash flow was negative for the first time in a decade. The market prices the stock at 11.7x trailing earnings and 0.84x book — below stated book value — implying it does not believe the FY2022 cycle peak is repeatable. The single financial metric that decides this stock is operating margin trajectory: every 100 bps of margin recovery on FY2025's revenue base adds roughly $9M, or ~13% to FY2025 net income.

Revenue, Margins, and Earnings Power

GNFC's top line is not a growth story; it is a price-mix story. Volume comes from regulated urea capacity plus chemical plants running near nameplate. Revenue therefore tracks the chemical-cycle realisation index and pass-through of urea subsidy. The operating margin is far more important than the revenue line.

The boom-bust pattern is unmistakable. FY2022 was a once-in-a-decade earnings surge driven by a global tightness in TDI, aniline and acetic acid following supply disruptions; net income roughly doubled FY2021 and the company earned more than its prior 4-year cumulative in a single year. By FY2024 most of that surge had unwound and the company nearly returned to its long-run base level. The market is pricing the average, not the peak.

Define operating margin: revenue minus operating expenses (cost of materials, employees, energy, other), divided by revenue. It excludes other income, interest and depreciation. A swing from 27.6% in FY2022 to 6.3% in FY2024 — a 21-point compression — speaks to an earnings stream with virtually no contractual stickiness. Mid-cycle margin sits in the 12–15% band; both 6% and 28% are extreme.

Recent quarterly trajectory: cycle searching for a bottom

Q1 FY2026 marked the cycle low (revenue $187M, 2% margin) on the back of a Bharuch maintenance shutdown and ammonia-plant production loss. Q2 and Q3 FY2026 have rebounded modestly to ~9% operating margin on stronger chemical volumes and slightly better realisations, while management explicitly notes that input costs (oil, gas, imported coal) eased 2–7% sequentially. The 9-month FY2026 PAT of ~$48M is up ~8% YoY despite weaker top-line — a pure margin story — but well below the ~$140M 9M run-rate of FY2023. The cycle is recovering, not booming.

Cash Flow and Earnings Quality

Define free cash flow: cash from operations minus capital expenditure. It is what is left for shareholders after the business has reinvested to maintain itself. Reported "FCF" here approximates this — Screener's CFO/FCF reconcile to roughly 92–179% of operating profit historically.

Over the 11-year window, cumulative CFO of approximately $1,628M has tracked cumulative net income of approximately $965M at a 1.69x ratio — exceptional, helped by depreciation add-back and a one-time working-capital release as the urea subsidy backlog was cleared (debtor days collapsed from 100 in FY2020 to 13 in FY2023). FY2024 was the outlier: CFO collapsed to $4M and FCF turned negative $26M as receivables rebuilt and capex stepped up. FY2025 normalised to $71M CFO but FCF was still only $18M because gross capex remained elevated.

The collapse in debtor days from 119 (FY2016) to 13 (FY2023) is the single most important earnings-quality story of the past decade. It reflects the central government's clean-up of subsidy arrears for urea producers, which directly converted balance-sheet receivables into cash. That tailwind is over — debtor days have stabilised in the 20–30 range. Future FCF will need to come from operating margin recovery, not working-capital release.

Balance Sheet and Financial Resilience

GNFC's balance sheet is its most underappreciated asset.

Debt has been progressively retired from a peak of $615M in FY2015 to a residual $12M in FY2025 — a balance-sheet transformation. Treasury investments climbed to a cycle peak of $390M in FY2023 before being drawn down to fund higher capex and elevated dividends. Net cash (investments minus debt) of approximately $258M equates to roughly 30% of the company's market cap. ICRA's most recent rating action on the company referenced an "AA-" long-term rating before withdrawal at the company's request — there is no longer a public bond programme to rate.

Returns, Reinvestment, and Capital Allocation

Define ROCE: earnings before interest and tax, divided by capital employed (debt + equity). It measures the productivity of every rupee invested in the business. GNFC's average ROCE across FY2016–FY2025 is ~16%; the spread between trough (8%) and peak (33%) is enormous. The decade weighted-average is decent for a cyclical commodity producer but well below specialty chemicals peers (Deepak Fertilisers 16%, Coromandel 23%, Chambal 27%).

Capital allocation: the dividend pivot

The capital-allocation regime changed materially in FY2023. Pre-cycle, GNFC paid 15–18% of earnings as dividend and used surplus FCF to extinguish debt. From FY2023 onwards the payout ratio reset to 32–49%, with $0.21/share declared for FY2025 at a 3.6% trailing yield — meaningful for a state-affiliated industrial. The promoter (Gujarat State Investments + GSFC, ~41% combined) has clear interest in steady dividend extraction; minority holders ride along.

Capex plans (per Q3 FY2026 investor presentation) are ramping:

• Under execution: Coal-based steam & power plant (Dahej), ammonia expansion (50 KTPA), Weak Nitric Acid-III (200 KTPA), Ammonium Nitrate-II (163 KTPA)
• Under consideration: BisPhenol-A (150 KTPA) and Polyols (100 KTPA) at Dahej

Share count was held at 155.4 million from FY2017 through FY2023 and then reduced to 147.0 million in FY2024 (a ~5.4% capital return; equity capital dropped from $19M to $18M of paid-up). That accounts for roughly half of FY2024's ~$154M financing outflow — combined with the higher dividend payout, FY2024 was the year management decisively pivoted from balance-sheet repair to shareholder return. Per-share book value has compounded from $4.45 in FY2018 to $6.82 in FY2025 — roughly 10% annual compounding, comfortably above India's risk-free rate.

Segment and Unit Economics

Granular segment financials are not directly available in the data feed (segment.json returned no detail), but management's quarterly investor decks provide a clear picture.

The chemicals segment is carrying the company. In 9M FY2026 it generated $53M of segment PBIT on $398M of revenue (~13% margin), more than offsetting a $19M loss in fertilizers and producing ~92% of group operating profit. Within chemicals, TDI (toluene diisocyanate, used in polyurethane foams), aniline, methanol and acetic acid are the swing products — feedstock spreads disclosed by management in INR per metric tonne are best read in their reported form because the relevant volatility is rupee-denominated:

The TDI–toluene spread (a proxy for one of GNFC's most profitable products) has compressed from ~₹102k/MT in Q3 FY2025 to ~₹97k/MT in Q3 FY2026 — still healthy, but no longer expanding. Aniline–benzene spread has held around ₹42k/MT. Methanol–acetic spreads have weakened. The fertilizer segment runs at a structural loss until the next round of urea price/energy revisions; management noted in Q3 FY2026 that revisions in both energy and fixed cost are expected by June 2026, which would reset segment economics.

Valuation and Market Expectations

Choice of valuation lens for GNFC: EV/EBITDA and P/B are the right gauges, not P/E, because reported earnings span a 5x range across the cycle.

EV is computed as market cap ($771M) + total debt ($12M) − treasury investments (~$270M) ≈ $539M. Operating EBITDA in FY2025 was $72M (op profit) + $35M (D&A) = ~$107M, giving EV/EBITDA of 5.0x at trough margins. At mid-cycle margins (12% op + D&A) EBITDA would normalise to ~$145M, implying ~3.7x EV/EBITDA.

Book value per share has compounded from $4.45 in FY2018 to $6.82 in FY2025 — a 10% CAGR. The current price of $5.25 sits 15% below stated book. Trough EPS of $0.48 maps to a fair P/E of ~12x; cycle-average EPS of ~$0.65 would map to a justified price closer to $7.62 even on a 12x multiple.

Peer Financial Comparison

Reading the peer table. GNFC sits in the cheap-and-mediocre quadrant. It is cheaper than the industry leaders (Coromandel, Chambal, Deepak) on every multiple, but those names earn three-times its current ROCE. The closer comparables are GSFC (sister Gujarat-state company, deeper P/B discount but worse ROE) and RCF (state-owned, more leveraged, similar ROE). On balance-sheet quality, GNFC and Chambal are the only two members of this set that are virtually debt-free. Coromandel and Deepak Fertilisers run materially higher leverage (Deepak $470M debt vs $689M equity).

The peer-relative discount on GNFC is deserved at trough margins (it earns less) but unjustified at mid-cycle margins (its capital structure is the cleanest after Chambal, and its valuation is the lowest after GSFC). The closing-of-discount thesis depends entirely on margin recovery.

What to Watch in the Financials

Closing financial verdict

The financials confirm that GNFC has financial quality (positive cumulative FCF, cash conversion above 100%, a fortress balance sheet, no dilution in over a decade, sustained dividend) that would be respectable at almost any commodity-chemicals operator in India. They contradict the narrative of a structurally broken business — there is no leverage problem, no working-capital crisis, no auditor concern, no goodwill bloat (intangibles are immaterial), no governance-driven balance-sheet engineering. What they expose is that this is a margin story, not a quality story: every dollar of investment thesis here lives or dies on whether commodity-chemical spreads recover.

The first financial metric to watch is operating margin, because every 100 bps of recovery on FY2025's revenue base adds approximately $9M — about 13% — to net income, and the Q3 FY2026 print of 9% is only halfway back to the 12–15% mid-cycle band.